DOCSLIB.ORG

Epigenetic Modifications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epigenetic Modifications Epigenetic modifications Histone modifications binding proteins hKAT3A hKAT3A (CBP) hKAT3A (CBP) Chromodomain proteins hKAT5B hKAT3B (p300) hKAT3B (p300) NH2 dKAT3 (dCBP/NEJ) dKAT3 (dCBP/NEJ) ac chromo CHD1 H3K4me2/3 RNF20/RNF40 Msk1 UBCH6 PKC N HP1/spSwi6 H3K9me2/3 MST1 hKAT3B ARDT1 ScRad6 TDG, ac MBT spChp1 H3K9me2/3 PRMT6 BER O N CDY1 H3K9me2/3 spMst1 P DNMT P ac ac adp ub spSir2 me PHD PC1/PC2/PC/LHP1 H3K27me3, H3K9me3 NH2 O NH2 PADI4 MSL3 H3K36me3 Replication C hKDM1 (LSD1/BHC110) S N OH N K K K K K me 14-3-3 hMRG15 H3K36me, H3K4me3 spKDM1 (Swm1/Saf110) ac dKDM1 (Su(var)3-3) me cit hKAT3A (CBP) scEaf3 H3K36me, H3K4me3 1 hKAT3B (p300) 14 15 20 30 120 hKDM2B (JHDM1b/FBXL10) cit hKDM5A (JARID1A/RBP2) dKAT3 (dCBP/NEJ) O N O N tudor CBX1,3,5 H3K9me3/2 hKDM5B (JARID1B/PLU1) hKAT1 hKAT5 TDG, MPP8 H3K9me3/2 hKDM5C (JARID1C/SMCX) R Replication K ScKAT5 BER hKDM5D (JARID1D/SMCY) ac 12 P bromo Tip60 H3K9me3/2 scKDM5 (Jhd2) 3 5caC 5mC spKDM5 (Jmj2) CBX2,4,6,7,8 H3K27me3/2, H3K9me3/2 PRMT6 ac chromo dKDM5 (Lid) hKAT1 (HAT1) ub ZF - CW ac Replication MBT proteins scKAT1 (Hat1) PRMT5 PRMT1 TET K spKAT1 (Hat1/Hag603) PADI4 PRMT6 TET PHF20L1 H3K4me1, H4K20me1 SETMAR ac MBT 5 dKAT1 (CG2051) iso ANKYRIN hKMT2A (MLL1) hKAT3A (CBP) PADI4 NH2 NH2 SFMBT H3K9me1/2, H4K20me1/2 hKMT2B (MLL2) K hKAT3B (p300) L3MBTL1 H4K20me1/2, H1bK26me1/2 me cit hKMT2C (MLL3) me dKAT3 (dCBP/NEJ) me PHD hKMT2D (MLL4) 5 N O N OH o-p PWWP SIRT6 hKAT5 (TIP60/PLIP) L3MBTL1 H3K20me hKMT2E (MLL5) scKAT5 (Esa1) ARTD1 ac chromo hKMT2F (hSET1A) spKAT5 (Mst1) me 14-3-3 L3MBTL1/2 H3K9me hKMT2G (hSET1B) O O hKAT1 (HAT1) adp R Haspin hKAT2A (hGCN5) N TET N dKAT5 (dTIP60) BRCT Vrk1 hKMT2H (ASH1) R hKAT7 (HBO1/MYST2) scKAT1 (Hat1) MBTD1 H3K20me hKAT2B (PCAF) adp spKAT1 (Hat1/Hag603) ac 2 hKMT3C (SMYD2) scKAT2 (Gcn5) 11 spKAT7 (Mst2) MBT hKMT3G (NSD3) PRMT1 dKAT7 (CHM) dKAT1 (CG2051) cit PHD proteinstudor spKAT2 (Gcn5) P BIR hKMT7 (SETD7) PRMT6 hKAT5 (TIP60/PLIP) dKAT2 (dGCN5/PCAF) 5fC AM-AR 5hmC scKAT5 (Esa1) P scKMT2 (Set1) me PHD scYng1 H3K4me2/3 hKAT12 (TFIIIC90) spKAT5 (Mst1) spKMT2 (Set1) K hKAT3A (CBP) P bromo AM-PD dKAT5 (dTIP60) ING1,2,3,4,5 H3K4me2/3 dKMT2A (Trx) hKAT3B (p300) me PRMT1 hKAT7 (HBO1/MYST2) hKDM1 (LSD1/BHC110) 13 CKII dKAT3 (dCBP/NEJ) BPTF/dmNURF301 H3K4me2/3 T PRMT5 spKAT7 (Mst2) me 14-3-3 hKDM3A (JHDM2a) ScCK1 PADI4 PRMT6 hKAT5 (TIP60/PLIP) ub ZF - CW Bmi/Ring1A dKAT7 (CHM) scSpp1 H3K4me2/3 3 ac me hKDM3B (JHDM2b) scKAT5 (Esa1) hKDM4A (JMJD2A/JHDM3A) spKAT5 (Mst1) scSet3 H3K4me2/3 hKDM4B (JMJD2B) R dKAT5 (dTIP60) cit tudor cit me ac hKAT5 (TIP60/PLIP) iso ANKYRIN hKDM4C (JMJD2C/GASC1) ub P hKAT7 (HBO1/MYST2) scJhd1 H3K4me3 hKDM4D (JMJD2D) 29 spKAT7 (Mst2) scKAT5 (Esa1) spKAT5 (Mst1) RAG2 H3K4me3 K scKDM4 (Rph1) NHK-1 dKAT7 (CHM) P bromo PKC beta PHF8 dKAT5 (dTIP60) o-p PWWP TAF3 H3K4me3 P 4 H2B H4 S R K hKAT8 (hMOF/MYST1) K scKAT8 (Sas2) ICBP90 (Np95) H3K9me2/3 ub ZF - CW BIR hKMT1A (SUV39H1) 1 3 5 spKAT8 (Mst2) P ac adp BRCT P hKMT1B (SUV39H2) 119 dKAT8 (dMOF/CG1894) JARID1C H3K9me3 hKMT1C (G9a) JARID1A H3K4me2/3 hKMT1D (EuHMTase/GLP) iso ANKYRIN me hKMT1E (ESET/SETDB1) T K SIRT2 P BIR KIAA1718 H3K4me2/3 T hKMT1F (CLL8) spSir2 Lid H3K4me2/3 hKMT8 (RIZ1) 8 ac o-p PWWP chromo 6 me cit 120 spKMT1 (Clr4) MLL1 H3K4me2/3 dKMT1 (Su(var)3-9) ARDT1 PHF2,8 H3K4me2/3 hKAT2A (hGCN5) adp BRCT PHD hKAT2B (PCAF) K R PP1 H2A hKMT5A (Pr-SET7/8) PHO23 H3K4me2/3 scKAT2 (Gcn5) ac adp hKMT5B (SUV4-20H1) ac me spKAT2 (Gcn5) 12 Pygo H3K4me2/3 8 hKMT5C (SUV4-20H2) P BIR dKAT2 (dGCN5/PCAF) ac chromo tudor Aurora B spKMT5 (Set9) hKAT3A (CBP) CHD4 H3K9me Pim1 dKMT5A (PR-set7) ac chromo hKAT3B (p300) MSK1 dKMT5B (Su(var)4-20) ICBP90 H3K9me dKAT3 (dCBP/NEJ) K K MSK2 hKMT3B (NSD1) ac MBT MBT hKAT6A (MOZ/MYST3) PP4 SMCX H3K9me IKK alpha 16 ac MBT 9 hKAT6B (MORF/MYST4) ac scKAT6 (Sas3) EYA1/3 DPF3 H3K14ac ZF - CW me spKAT6 (Mst2) Mst1 bromo me PHD P dKAT6 (CG1894) ATM me 14-3-3 PHDproteins DLK/ZIP hKAT10 ATR WSTF Lpcat1 14-3-3 H3S10p, H3S28p PRK1 scKAT10 (Hap2) H2AX H3 me 14-3-3 me hKAT12 (TFIIIC90) K me 14-3-3 S Tudor proteins ac ub P P HAT4 chromo me 20 o-p accit chromotudor 10 P hPRMT4 cit tudor JMJD2A H3K4me3, H4K20me3 BBAP/DTX3L tudor 53BP1 H4K20me1/2 PADI4 acP bromoMBT PHD K K S Y S spCrb2 H4K20me2 T P bromo 5 119 139 142 47 ac ub PHF20 H4K20me2 11 ac hKAT2A (hGCN5) MBT P ac meub ZFPHD - CW MBT hKAT2B (PCAF) ub ZF - CW TDRD3 H3R17me2a, H4R3me2a scKAT2 (Gcn5) 14-3-3 spKAT2 (Gcn5) hPRMT4 PWWP bromo scSgf29 H3K4me2/3 ac chromo P K iso ANKYRIN ANKYRIN K dKAT2 (dGCN5/PCAF) me 14-3-3 Epigenetic modifications hHDAC1 iso ANKYRIN PHF19 H3K36me3 hKAT3A (CBP) BRCT 91 14 me cit hKAT3B (p300) PADI4 hHDAC2 PHF1 H3K36me3 Histone modifications and DNA ac chromo dKAT3 (dCBP/NEJ) o-pcit PWWPtudor hKAT12 (TFIIIC90) o-p PWWP methylation are epigeneticac marks that MBT ac chromo hKAT3B (P300) Bromodomain proteins scKAT11 (Rtt109) R adp affect gene expression. This poster highlights spKAT11 (Rtt109) P bromoBRCT Polybromo/BAF180 H3ac ac ac ac hKAT2A (hGCN5) hKAT2A (GCN5) adp BRCT scSnf2 H3ac, H4ac the different types of epigenetic modifications MBT 17 hKAT3B (p300) hKAT2B (PCAF) me ac hKAT3A scKAT2 (Gcn5) Brd2,3,4,7 H3ac, H4ac PHD MBT hKAT5B ubP ZFBIR - CW and their writers, readers, and erasers. bromo spKAT2 (Gcn5) hKMT4 (DOT1L) P BIR KDM6A (UTX) dKAT2 (dGCN5/PCAF) scKMT4 (Dot1) TAF1 H3ac, H4ac R KDM6B (JMJD3) me PHD P/CAF H3ac, H4ac, H4K16ac 18 ac iso ANKYRIN Epigenetic modificationsme at Abcam 14-3-3 me PHD hKDM2A (JHDM1a/FBXL11) CBP/p300 H3ac, H4ac hKMT6B (EZH1) hKDM2B (JHDM1b/FBXL10) ac me ac chromo hKMT6 (EZH2) To help support your research, we have a range ofac chromo scKDM2 (Jhd1) hPKC-delta o-pac chromoPWWP scBdf1 H4ac hKMT3G (NSD) hKDM4A (JMJD2A/JHDM3A) ac chromo ac chromo me 14-3-3 K dKMT6 (E/(Z)) hBRG1 H3K14ac resources, including sample preparation kits, detection assays hKDM4B (JMJD2B) ac MBT hKDM4C (JMJD2C/GASC1) scRsc1,2,4 H3K14ac (Rsc4) cit tudor me 14-3-3 23 me cit K K adpac BRCTMBT for epigenetic modifications, recombinant active proteins, scKDM4 (Rph1) P ac ac chromo ac MBT ARTD1 dKDM2 Rv1988 56 79 MBT scGcn5 H4ac, H4K16ac inhibitors of epigenetic pathways, and peptide array-tested me PHD ac chromoMBT cit tudor ATAD2 H3K14ac monoclonal antibodies to histone modifications. R meacP chromoPHDBIR P bromo cit tudor ac me adp hKMT3A (SET2) T me PHD BRDT H4K5ac, H4K8ac, H3K18ac 26 hKMT3B (NSD1) me me 14-3-3 MSK1 hJAK2 CBP/p300 H4K20ac, H3K36ac ac MBT me PHD hKMT3C (SMYD2) 45 meac 14-3-3MBT MSK2 NSD2 To find out more, check meacout our epigeneticsMBTPHD contentP library wherebromo you can me 14-3-3 GCN5 H4K16ac scKMT3 (Set2) cit tudor K spKMT3 (Set2) ub ZF - CW P bromo P R mecit PB-2 H3K14ac find more posters, guides, protocols, and webinars. Zfh Setd3 tudorPHD me PHD me 14-3-3 27 P 42 cit tudor TRIM24 H3K23ac P bromo me 14-3-3PHD ub ZF - CW scFPR4 ARTD1 scFPR4 www.abcam.com/epigenetics Y meP ZF-CWbromo14-3-3 proteins iso ANKYRIN ub ZF - CW S P bromo 41 ub ZF - CW ZCWPW1 H3K4me1/2 me 14-3-3 cit tudor adp me 28 iso ac me iso ubcit ZFtudor - CW ac chromo mecit 14-3-3tudor iso ANKYRIN ub ANKYRINZF - CW proteins iso ANKYRIN ANKYRIN chromo Histoneac modificationschromo o-p PWWP iso isoP ANKYRINbromo G9a/GLP H3K9me2/1 P K K P iso ANKYRIN ac chromo cit tudor P bromo ac chromo 30 36 37 38 o-p PWWPPWWP proteins ac AcetylationchromoMBT citP Deiminationbromotudor o-p O-palmitoylationPWWP P o-pub ZFPWWP - CW o-p PWWP BRPF1 H3K36me3 ac MBT adp BRCT o-p PWWP ac MBT 14-3-3 adp BRCT DNMT3A H3K36me3 ac DeacetylationMBT P Phosphorylationbromo ub UbiquitinationZF - CW adpiso ANKYRINBRCT adp PDP1 H4K20me1 meac MBTPHD ubP ZFbromo - CW adp BRCT me BRCTPHD me P BIR BIR adp HDGF2 H3K36me3 me MethylationPHD P Dephosphorylation ADPRibosylationBRCT o-pP PWWPBIR BIR me PHD ub ZF - CW iso ANKYRIN chromo meP BRCT 14-3-3proteins ANKYRIN BIR me Demethylation14-3-3PHD isoub IsomerizationZF - CW P adp BRCT MDC1 H2AXS139p (γH2AX) PWWP me 14-3-3 P BIR cit tudor BIR proteins ANKYRIN me 14-3-3 iso o-p PWWP P BIR ANKYRIN Survivin H3T3p Createdmecit by Abcam 14-3-3intudor collaboration witho-piso Tony KouzaridesPWWP and Andy Bannister (Gurdon Institute, Cambridge). P bromo cit tudor cit tudor o-p PWWP adp BRCT ub ZF - CW citP bromotudor o-padp PWWPBRCT P bromo iso ANKYRIN Copyright ©P 2018 Abcam, All rightsbromo reserved. adp BRCT P BIR ubP ZFbromo - CW adpP BRCTBIR o-p PWWP ub ZF - CW ub ZF - CW P BIR adp BRCT isoub ANKYRINZF - CW P BIR iso ANKYRIN P BIR iso ANKYRIN o-piso ANKYRINPWWP o-p PWWP o-p PWWP o-padp PWWPBRCT adp BRCT adp BRCT adpP BRCTBIR P BIR P BIR P BIR.
Load more

Recommended publications
  • Combinatorial Genetic Control of Rpd3s Through Histone H3K4 and H3K36 Methylation
    bioRxiv preprint doi: https://doi.org/10.1101/376046; this version posted July 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Combinatorial Genetic Control of Rpd3S through histone H3K4 and H3K36 Methylation 2 in Budding Yeast 3 4 Kwan Yin Lee*, Mathieu Ranger*, and Marc D. Meneghini* 5 *Department of Molecular Genetics, University of Toronto, ON, M5S 1A8, Canada 6 Running title: Rpd3S control by H3K4me and H3K36me 7 Keywords: Rpd3S; histone methylation; SET1; JHD2; RPH1; SET2 8 Corresponding author mailing addresses: 9 Marc Meneghini 10 Dept. of Molecular Genetics University of Toronto 11 MaRS2 1532 12 661 University Avenue 13 Toronto, ON M5G 1M1 14 Office: 416-978-7578 15 Fax: 416-978-6885 16 email: [email protected] 17 18 19 1 bioRxiv preprint doi: https://doi.org/10.1101/376046; this version posted July 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Abstract 2 Much of euchromatin regulation occurs through reversible methylation of histone H3 3 lysine-4 and lysine-36 (H3K4me and H3K36me). Using the budding yeast Saccharomyces 4 cerevisiae, we previously found that levels of H3K4me modulated temperature sensitive alleles 5 of the transcriptional elongation complex Spt6-Spn1 through an unknown H3K4me effector 6 pathway. Here we identify the Rpd3S histone deacetylase complex as the H3K4me effector 7 underlying these Spt6-Spn1 genetic interactions.
    [Show full text]
  • Recognition of Cancer Mutations in Histone H3K36 by Epigenetic Writers and Readers Brianna J
    EPIGENETICS https://doi.org/10.1080/15592294.2018.1503491 REVIEW Recognition of cancer mutations in histone H3K36 by epigenetic writers and readers Brianna J. Kleina, Krzysztof Krajewski b, Susana Restrepoa, Peter W. Lewis c, Brian D. Strahlb, and Tatiana G. Kutateladzea aDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA; bDepartment of Biochemistry & Biophysics, The University of North Carolina School of Medicine, Chapel Hill, NC, USA; cWisconsin Institute for Discovery, University of Wisconsin, Madison, WI, USA ABSTRACT ARTICLE HISTORY Histone posttranslational modifications control the organization and function of chromatin. In Received 30 May 2018 particular, methylation of lysine 36 in histone H3 (H3K36me) has been shown to mediate gene Revised 1 July 2018 transcription, DNA repair, cell cycle regulation, and pre-mRNA splicing. Notably, mutations at or Accepted 12 July 2018 near this residue have been causally linked to the development of several human cancers. These KEYWORDS observations have helped to illuminate the role of histones themselves in disease and to clarify Histone; H3K36M; cancer; the mechanisms by which they acquire oncogenic properties. This perspective focuses on recent PTM; methylation advances in discovery and characterization of histone H3 mutations that impact H3K36 methyla- tion. We also highlight findings that the common cancer-related substitution of H3K36 to methionine (H3K36M) disturbs functions of not only H3K36me-writing enzymes but also H3K36me-specific readers. The latter case suggests that the oncogenic effects could also be linked to the inability of readers to engage H3K36M. Introduction from yeast to humans and has been shown to have a variety of functions that range from the control Histone proteins are main components of the of gene transcription and DNA repair, to cell cycle nucleosome, the fundamental building block of regulation and nutrient stress response [8].
    [Show full text]
  • Automethylation of PRC2 Promotes H3K27 Methylation and Is Impaired in H3K27M Pediatric Glioma
    Downloaded from genesdev.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma Chul-Hwan Lee,1,2,7 Jia-Ray Yu,1,2,7 Jeffrey Granat,1,2,7 Ricardo Saldaña-Meyer,1,2 Joshua Andrade,3 Gary LeRoy,1,2 Ying Jin,4 Peder Lund,5 James M. Stafford,1,2,6 Benjamin A. Garcia,5 Beatrix Ueberheide,3 and Danny Reinberg1,2 1Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York 10016, USA; 2Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA; 3Proteomics Laboratory, New York University School of Medicine, New York, New York 10016, USA; 4Shared Bioinformatics Core, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA; 5Department of Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA The histone methyltransferase activity of PRC2 is central to the formation of H3K27me3-decorated facultative heterochromatin and gene silencing. In addition, PRC2 has been shown to automethylate its core subunits, EZH1/ EZH2 and SUZ12. Here, we identify the lysine residues at which EZH1/EZH2 are automethylated with EZH2-K510 and EZH2-K514 being the major such sites in vivo. Automethylated EZH2/PRC2 exhibits a higher level of histone methyltransferase activity and is required for attaining proper cellular levels of H3K27me3. While occurring inde- pendently of PRC2 recruitment to chromatin, automethylation promotes PRC2 accessibility to the histone H3 tail. Intriguingly, EZH2 automethylation is significantly reduced in diffuse intrinsic pontine glioma (DIPG) cells that carry a lysine-to-methionine substitution in histone H3 (H3K27M), but not in cells that carry either EZH2 or EED mutants that abrogate PRC2 allosteric activation, indicating that H3K27M impairs the intrinsic activity of PRC2.
    [Show full text]
  • Screening for Genes That Accelerate the Epigenetic Aging Clock in Humans Reveals a Role for the H3K36 Methyltransferase NSD1 Daniel E
    Martin-Herranz et al. Genome Biology (2019) 20:146 https://doi.org/10.1186/s13059-019-1753-9 RESEARCH Open Access Screening for genes that accelerate the epigenetic aging clock in humans reveals a role for the H3K36 methyltransferase NSD1 Daniel E. Martin-Herranz1,2* , Erfan Aref-Eshghi3,4, Marc Jan Bonder1,5, Thomas M. Stubbs2, Sanaa Choufani6, Rosanna Weksberg6, Oliver Stegle1,5,7, Bekim Sadikovic3,4, Wolf Reik8,9,10*† and Janet M. Thornton1*† Abstract Background: Epigenetic clocks are mathematical models that predict the biological age of an individual using DNA methylation data and have emerged in the last few years as the most accurate biomarkers of the aging process. However, little is known about the molecular mechanisms that control the rate of such clocks. Here, we have examined the human epigenetic clock in patients with a variety of developmental disorders, harboring mutations in proteins of the epigenetic machinery. Results: Using the Horvath epigenetic clock, we perform an unbiased screen for epigenetic age acceleration in the blood of these patients. We demonstrate that loss-of-function mutations in the H3K36 histone methyltransferase NSD1, which cause Sotos syndrome, substantially accelerate epigenetic aging. Furthermore, we show that the normal aging process and Sotos syndrome share methylation changes and the genomic context in which they occur. Finally, we found that the Horvath clock CpG sites are characterized by a higher Shannon methylation entropy when compared with the rest of the genome, which is dramatically decreased in Sotos syndrome patients. Conclusions: These results suggest that the H3K36 methylation machinery is a key component of the epigenetic maintenance system in humans, which controls the rate of epigenetic aging, and this role seems to be conserved in model organisms.
    [Show full text]
  • Mechanism for Epigenetic Variegation of Gene Expression at Yeast Telomeric Heterochromatin
    Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Mechanism for epigenetic variegation of gene expression at yeast telomeric heterochromatin Tasuku Kitada,1,2 Benjamin G. Kuryan,1,2 Nancy Nga Huynh Tran,1,2 Chunying Song,1,2 Yong Xue,1,2 Michael Carey,1,2 and Michael Grunstein1,2,3 1Department of Biological Chemistry, David Geffen School of Medicine, 2the Molecular Biology Institute, University of California at Los Angeles, Los Angeles, California 90095, USA Yeast contains heterochromatin at telomeres and the silent mating-type loci (HML/HMR). Genes positioned within the telomeric heterochromatin of Saccharomyces cerevisiae switch stochastically between epigenetically bistable ON and OFF expression states. Important aspects of the mechanism of variegated gene expression, including the chromatin structure of the natural ON state and the mechanism by which it is maintained, are unknown. To address this issue, we developed approaches to select cells in the ON and OFF states. We found by chromatin immunoprecipitation (ChIP) that natural ON telomeres are associated with Rap1 binding and, surprisingly, also contain known characteristics of OFF telomeres, including significant amounts of Sir3 and H4K16 deacetylated nucleosomes. Moreover, we found that H3K79 methylation (H3K79me), H3K4me, and H3K36me, which are depleted from OFF telomeres, are enriched at ON telomeres. We demonstrate in vitro that H3K79me, but not H3K4me or H3K36me, disrupts transcriptional silencing. Importantly, H3K79me does not significantly reduce Sir complex binding in vivo or in vitro. Finally, we show that maintenance of H3K79me at ON telomeres is dependent on transcription. Therefore, although Sir proteins are required for silencing, we propose that epigenetic variegation of telomeric gene expression is due to the bistable enrichment/depletion of H3K79me and not the fluctuation in the amount of Sir protein binding to nucleosomes.
    [Show full text]
  • Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination
    Published OnlineFirst July 1, 2014; DOI: 10.1158/1078-0432.CCR-13-2499 Clinical Cancer Molecular Pathways Research Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination Teresa Ezponda and Jonathan D. Licht Abstract Methylation of lysine 27 on histone H3 (H3K27me), a modification associated with gene repression, plays a critical role in regulating the expression of genes that determine the balance between cell differentiation and proliferation. Alteration of the level of this histone modification has emerged as a recurrent theme in many types of cancer, demonstrating that either excess or lack of H3K27 methylation can have oncogenic effects. Cancer genome sequencing has revealed the genetic basis of H3K27me deregulation, including mutations of the components of the H3K27 methyltransferase complex PRC2 and accessory proteins, and deletions and inactivating mutations of the H3K27 demethylase UTX in a wide variety of neoplasms. More recently, mutations of lysine 27 on histone H3 itself were shown to prevent H3K27me in pediatric glioblastomas. Aberrant expression or mutations in proteins that recognize H3K27me3 also occur in cancer and may result in misinterpretation of this mark. In addition, due to the cross-talk between different epigenetic modifications, alterations of chromatin modifiers controlling H3K36me, or even mutations of this residue, can ultimately regulate H3K27me levels and distribution across the genome. The significance of mutations altering H3K27me is underscored by the fact that many tumors harboring such lesions often have a poor clinical outcome. New therapeutic approaches targeting aberrant H3K27 methylation include small molecules that block the action of mutant EZH2 in germinal center-derived lymphoma.
    [Show full text]
  • Corrections and Retraction
    Corrections and Retraction CORRECTIONS RETRACTION CELL BIOLOGY MEDICAL SCIENCES Correction for “A small molecule accelerates neuronal differ- Retraction for “Wnt-5a signaling restores tamoxifen sensitivity in entiation in the adult rat,” by Heiko Wurdak, Shoutian Zhu, estrogen receptor-negative breast cancer cells,” by Caroline E. Kyung Hoon Min, Lindsey Aimone, Luke L. Lairson, James Ford, Elin J. Ekström, and Tommy Andersson, which appeared Watson, Gregory Chopiuk, James Demas, Bradley Charette, in issue 10, March 10, 2009, of Proc Natl Acad Sci USA Eranthie Weerapana, Benjamin F. Cravatt, Hollis T. Cline, Eric (106:3919–3924; first published February 23, 2009; 10.1073/ C. Peters, Jay Zhang, John R. Walker, Chunlei Wu, Jonathan pnas.0809516106). Chang, Tove Tuntland, Charles Y. Cho, and Peter G. Schultz, The authors wish to note the following: “During efforts to which appeared in issue 38, September 21, 2010, of Proc Natl extend this work, we re-examined the laboratory records for all Acad Sci USA (107:16542–16547; first published September 7, figures and found that the Excel files on which Fig. 4C was based 2010; 10.1073/pnas.1010300107). contained serious calculation errors; the first author of the paper The authors note that Rajkumar Halder should be added takes full responsibility for these inaccuracies. Considering the to the author line between Bradley Charette and Eranthie importance of this figure for the conclusions drawn, the authors Weerapana. Rajkumar Halder should be credited with contrib- hereby retract the work. We apologize for any inconvenience this uting new reagents/analytic tools. The online version has been may have caused.” corrected.
    [Show full text]
  • Targeted Demethylation of H3k9me3 and H3k36me3 Improves Somatic Cell Reprogramming
    bioRxiv preprint doi: https://doi.org/10.1101/699181; this version posted July 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Targeted demethylation of H3K9me3 and H3K36me3 improves somatic cell reprogramming 2 into cloned preimplantation but not postimplantation bovine concepti 3 4 Running title: KDM4B expression improves bovine somatic cell reprogramming in vitro but not in 5 vivo 6 7 Authors: Fanli Meng1, Kathrin Stamms1,2, Romina Bennewitz1,3, Andria Green1, Fleur Oback1, 8 Pavla Turner1, Jingwei Wei1,4 and Björn Oback1,3# 9 10 Author affiliations: 11 1AgResearch Ruakura Research Centre, Hamilton, New Zealand 12 2Present address: Institute of Nutrition, University Jena, Jena, Germany. 13 3Present address: Institute of Neurology, University Hospital Frankfurt, Frankfurt, Germany. 14 15 4Animal Science Institute, Guangxi University, Nanning, P.R China 16 5School of Medical Sciences, University of Auckland, Auckland, New Zealand 17 18 19 Key words: histone methylation, H3K9me3, H3K36me3, KDM4B, epigenetic reprogramming, 20 somatic cell transfer, embryo, totipotency, cattle, cloning efficiency, quiescence 21 22 #Corresponding Author: Björn Oback 23 AgResearch Ruakura Research Centre, Hamilton, New Zealand 24 Tel +64 7 838 5542, Fax +64 7 838 5536 25 E-mail [email protected] 26 1 bioRxiv preprint doi: https://doi.org/10.1101/699181; this version posted July 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 27 ABSTRACT 28 Correct reprogramming of epigenetic marks in the donor nuclei is a prerequisite for successful 29 cloning by somatic cell transfer.
    [Show full text]
  • Histone Methylation Regulation in Neurodegenerative Disorders
    International Journal of Molecular Sciences Review Histone Methylation Regulation in Neurodegenerative Disorders Balapal S. Basavarajappa 1,2,3,4,* and Shivakumar Subbanna 1 1 Division of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA; [email protected] 2 New York State Psychiatric Institute, New York, NY 10032, USA 3 Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA 4 New York University Langone Medical Center, Department of Psychiatry, New York, NY 10016, USA * Correspondence: [email protected]; Tel.: +1-845-398-3234; Fax: +1-845-398-5451 Abstract: Advances achieved with molecular biology and genomics technologies have permitted investigators to discover epigenetic mechanisms, such as DNA methylation and histone posttransla- tional modifications, which are critical for gene expression in almost all tissues and in brain health and disease. These advances have influenced much interest in understanding the dysregulation of epigenetic mechanisms in neurodegenerative disorders. Although these disorders diverge in their fundamental causes and pathophysiology, several involve the dysregulation of histone methylation- mediated gene expression. Interestingly, epigenetic remodeling via histone methylation in specific brain regions has been suggested to play a critical function in the neurobiology of psychiatric disor- ders, including that related to neurodegenerative diseases. Prominently, epigenetic dysregulation currently brings considerable interest as an essential player in neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic lateral sclerosis (ALS) and drugs of abuse, including alcohol abuse disorder, where it may facilitate connections between genetic and environmental risk factors or directly influence disease-specific Citation: Basavarajappa, B.S.; Subbanna, S.
    [Show full text]
  • Set1/COMPASS Repels Heterochromatin Invasion at Euchromatic Sites by Disrupting Suv39/Clr4 Activity and Nucleosome Stability
    Downloaded from genesdev.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Set1/COMPASS repels heterochromatin invasion at euchromatic sites by disrupting Suv39/Clr4 activity and nucleosome stability R.A. Greenstein,1,2 Ramon R. Barrales,3,4,5 Nicholas A. Sanchez,1,2 Jordan E. Bisanz,1 Sigurd Braun,3,4 and Bassem Al-Sady1 1Department of Microbiology and Immunology, George Williams Hooper Foundation, University of California at San Francisco, San Francisco, California 94143, USA; 2TETRAD Graduate Program, University of California at San Francisco, San Francisco, California 94143, USA; 3Department of Physiological Chemistry, Biomedical Center (BMC), Ludwig Maximilians University of Munich, 82152 Martinsried, Germany; 4International Max Planck Research School for Molecular and Cellular Life Sciences, 82152 Martinsried, Germany Protection of euchromatin from invasion by gene-repressive heterochromatin is critical for cellular health and viability. In addition to constitutive loci such as pericentromeres and subtelomeres, heterochromatin can be found interspersed in gene-rich euchromatin, where it regulates gene expression pertinent to cell fate. While heterochro- matin and euchromatin are globally poised for mutual antagonism, the mechanisms underlying precise spatial encoding of heterochromatin containment within euchromatic sites remain opaque. We investigated ectopic heterochromatin invasion by manipulating the fission yeast mating type locus boundary using a single-cell spreading reporter system. We found that heterochromatin repulsion is locally encoded by Set1/COMPASS on certain actively transcribed genes and that this protective role is most prominent at heterochromatin islands, small domains interspersed in euchromatin that regulate cell fate specifiers. Sensitivity to invasion by heterochromatin, surprisingly, is not dependent on Set1 altering overall gene expression levels.
    [Show full text]
  • Deregulation of Epigenetic Marks Is Correlated to Differential Exon Usage of Developmental Genes
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.17.423086; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Deregulation of epigenetic marks is correlated to differential exon usage of developmental genes authors: Hoang Thu Trang Do#1, Siba Shanak#1,2, Ahmad Barghash1,3, Volkhard Helms§1 #: equal contribution §: corresponding author 1: Saarland University, Center for Bioinformatics, 66041 Saarbruecken, Germany 2: Arab American University, Dept. for Biology and Biotechnology, Jenin, Palestine 3: German Jordanian University, School of Electrical Engineering and Information Technology, Amman, Jordan bioRxiv preprint doi: https://doi.org/10.1101/2020.12.17.423086; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Alternative exon usage is known to affect a large portion of genes in mammalian genomes. Importantly, different splice forms sometimes lead to distinctly different protein functions. We analyzed data from the Human Epigenome Atlas (version 9) whereby we connected the differential usage of exons in various developmental stages of human cells/tissues to differential epigenetic modifications at the exon level. In total, we analyzed 19 human tissues, adult cells, and cultured cells that mimic early developmental stages. We found that the differential occurrence of protein isoforms across developmental stages was often associated with changes in histone marks at exon boundary regions. Many of the genes that are differentially regulated at the exon level were found to be functionally associated with development and metabolism.
    [Show full text]
  • TRIM29 Regulates the Assembly of DNA Repair Proteins Into Damaged Chromatin
    ARTICLE Received 4 Feb 2015 | Accepted 27 Apr 2015 | Published 22 Jun 2015 DOI: 10.1038/ncomms8299 TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin Yasushi Masuda1, Hidehisa Takahashi1, Shigeo Sato2, Chieri Tomomori-Sato2, Anita Saraf2, Michael P. Washburn2,3, Laurence Florens2, Ronald C. Conaway2,4, Joan W. Conaway2,4 & Shigetsugu Hatakeyama1 Although DNA double-strand break (DSB) repair is mediated by numerous proteins accu- mulated at DSB sites, how DNA repair proteins are assembled into damaged chromatin has not been fully elucidated. Here we show that a member of the tripartite motif protein family, TRIM29, is a histone-binding protein responsible for DNA damage response (DDR). We found that TRIM29 interacts with BRCA1-associated surveillance complex, cohesion, DNA- PKcs and components of TIP60 complex. The dynamics of the TRIM29-containing complex on H2AX nucleosomes is coordinated by a cross-talk between histone modifications. TRIM29 binds to modified histone H3 and H4 tails in the context of nucleosomes. Furthermore, chromatin binding of TRIM29 is required for the phosphorylation of H2AX and cell viability in response to ionizing radiation. Our results suggest that TRIM29 functions as a scaffold protein to assemble DNA repair proteins into chromatin followed by efficient activation of DDR. 1 Department of Biochemistry, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan. 2 Stowers Institute for Medical Research, 1000 East, 50th Street, Kansas City, Missouri 64110, USA. 3 Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, Kansas 6616, USA. 4 Department of Biochemistry and Molecular Biology, Kansas University Medical Center, Kansas City, Kansas 66160, USA.
    [Show full text]